The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://tamzinkhfe014611.blogcudinti.com/38985417/retatrutide-vs-tirzepatide-a-comparative-analysis